<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="197562">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00519025</url>
  </required_header>
  <id_info>
    <org_study_id>PRO07080006</org_study_id>
    <secondary_id>investigator funding</secondary_id>
    <nct_id>NCT00519025</nct_id>
  </id_info>
  <brief_title>Risk Factors for Linezolid Resistance in Staphylococcus Aureus</brief_title>
  <official_title>Risk Factors for Linezolid Resistance in Staphylococcus Aureus</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Pittsburgh</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Pittsburgh</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a retrospective chart review study. The proposed study aims to document the risk
      factors for quinolone resistance in bloodstream isolates of Klebsiella species.
      Additionally, the adequacy of empiric antibiotic therapy for Klebsiella bloodstream
      infections will be assessed.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a retrospective chart review study. The proposed study aims to document the risk
      factors for quinolone resistance in bloodstream isolates of Klebsiella species.
      Additionally, the adequacy of empiric antibiotic therapy for Klebsiella bloodstream
      infections will be assessed. This research is important because identification of risk
      factors may allow earlier initiation of appropriate therapy in patients infected with these
      bacteria. Additionally, we will identify whether horizontal spread is responsible for this
      increasing trend.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>August 2007</start_date>
  <completion_date type="Anticipated">December 2016</completion_date>
  <primary_completion_date type="Anticipated">December 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">360</enrollment>
  <condition>Linezolid Resistance</condition>
  <condition>Staphylococcus Aureus</condition>
  <eligibility>
    <study_pop>
      <textblock>
        linezolid resistance to staph aureus
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  patients with linezolid resistance to staphylococcus aureus

        Exclusion Criteria:

          -  those that don't meet entry criteria
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Brian Potoski, PharmD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Pittsburgh</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Pittsburgh Medical Center</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15213</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2015</verification_date>
  <lastchanged_date>December 16, 2015</lastchanged_date>
  <firstreceived_date>August 17, 2007</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Linezolid</keyword>
  <keyword>Staphylococcus Aureus</keyword>
  <keyword>Infections</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Linezolid</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
